Patient Demographics and Clinical Characteristics
| Characteristic | Data |
| Total patients (n) | 219 |
| Mean age (y) | 68 (range, 46–87) |
| Median PSA (ng/mL) | 8.0 (range, 0.2–9,708) |
| Disease stage at time of 18F-NaF PET/CT (n) | |
| Staging | 129 |
| Biochemical recurrence | 67 |
| mCRPC | 23 |
| Gleason score (n) | |
| <7 | 17 (8%) |
| 7 | 121 (55%) |
| 8 | 31 (14%) |
| 9 | 38 (17%) |
| 10 | 2 (1.0%) |
| Unknown | 10 (5%) |
| T-stage (n) | |
| T1 | 66 (30%) |
| T2 | 86 (39%) |
| T3 | 49 (22%) |
| T4 | 11 (5%) |
| Unknown | 7 (4%) |
PSA = prostate-specific antigen; mCRPC = metastatic castration-resistant PCa.